ACC: J&J, Bayer's blood thinner Xarelto scores in artery disease post-surgery

28th March 2020 Uncategorised 0

Johnson & Johnson and Bayer’s legacy blood thinner Xarelto has had a tough year with competitors picking up steam and prescriptions leveling off. But in a hard-to-treat artery disease, Xarelto just posted a new trial in recent post-surgery patients. 

More: ACC: J&J, Bayer's blood thinner Xarelto scores in artery disease post-surgery
Source: fierce